What's Happening?
Eli Lilly has announced positive results from its Phase 3 ACHIEVE-4 trial, which evaluated the efficacy and safety of Foundayo (orforglipron) compared to insulin glargine in adults with type 2 diabetes and obesity. The study, which is the largest and longest
of its kind for Foundayo, involved over 2,700 participants across 15 countries. Foundayo met its primary endpoint by demonstrating a non-inferior risk of major adverse cardiovascular events compared to insulin glargine. Additionally, Foundayo showed superior improvements in A1C and body weight over 52 weeks, with a 57% lower risk of all-cause death compared to insulin glargine.
Why It's Important?
The results of the ACHIEVE-4 trial are significant as they reinforce Foundayo's potential as a treatment option for type 2 diabetes, particularly for patients with elevated cardiovascular risk. The study's findings could influence treatment guidelines and offer a new therapeutic option that combines efficacy with a favorable safety profile. This development is crucial for Eli Lilly as it seeks to expand its portfolio in the diabetes care market. The positive outcomes may also impact the pharmaceutical industry by setting new standards for diabetes treatment and encouraging further research into similar therapies.
What's Next?
Eli Lilly plans to submit Foundayo for approval to the U.S. Food and Drug Administration by the end of the second quarter. If approved, Foundayo could become a key player in the diabetes treatment market, offering a once-daily oral option without food or water restrictions. The company will likely focus on marketing strategies to promote Foundayo's benefits and differentiate it from existing treatments. Stakeholders, including healthcare providers and patients, will be closely monitoring the FDA's decision and the potential impact on diabetes management practices.
